NRX Pharmaceuticals
Manufacturing · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1201 N Orange St Ste 600, Wilmington, De...Phone Number
(484) 254-6134Website
www.nrxpharma.comRevenue
<$5 MillionStock Symbol
NRXPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for central nervous system disorders, including life-threatening forms of depression and post-traumatic stress disorder. It uses a scientific platform targeting the brains NMDA receptor to advance drug candidates such as preservative-free ketamine formulations and oral therapies designed to address unmet needs in severe mental health conditions. The company also supports healthcare delivery through its interventional psychiatry clinic network.Explore more
NRX Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NRX Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once NRX Pharmaceuticals has new funding data
Check if NRX Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at NRX Pharmaceuticals
Earning: See what the market has to say on NRX Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when NRX Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Click to see if NRX Pharmaceuticals had a recent Job posting/layoffs
NRX Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if NRX Pharmaceuticals is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NRX Pharmaceuticals
Compare insights from companies similar to NRX Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NRX Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NRX Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NRX Pharmaceuticals.
NRX Pharmaceuticals financials insights
Gather financial insights about NRX Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$25M
Debt
$11M
2024
Share Placement
$5M
Debt
$16M
2025
Other Financing Round
$8.9M
NRX Pharmaceuticals Tech Stack
A closer look at the technologies used by NRX Pharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Glenn Tyson has recently joined the organization as Chief Commercial Officer.
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Project
NRX Pharmaceuticals has noted that the upcoming trial involves only a day or a couple of days of D-cycloserine treatment rather than six weeks, reducing the risk that patients might not be compliant with the study drug to near zero.
Pharmaceuticals, Clinical Operations, Patient Experience
Project
Pharmaceuticals, Artificial Intelligence, Healthcare Technology
NRX Pharmaceuticals News & Media
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the Company”) announces the presentation of a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology annual conference documenting Real World Evidence of effectiveness associated with the use of intravenous (IV) ketamine to treat depression compared to intranasal esketamine. The presentation, entitled “Real World Evidence of Clinical Treatment Response Following Intravenous Racemic Ketamine VersNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock CapitalNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the “Offering”) of 5,714,286 shares of its common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $3.50 per share of Common Stock.NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its common stock, par value $0.001 per share (“Common Stock”) in an underwritten public offering (the “Offering”). The Company also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Common
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NRX Pharmaceuticals
Sign Up For FreeTo access detailed company insights
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for central nervous system disorders, including life-threatening forms of depression and post-traumatic stress disorder. It uses a scientific platform targeting the brains NMDA receptor to advance drug candidates such as pr... Read More
